Page last updated: 2024-11-04

octanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

octanoic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #1764 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

octanoic acid : A straight-chain saturated fatty acid that is heptane in which one of the hydrogens of a terminal methyl group has been replaced by a carboxy group. Octanoic acid is also known as caprylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID379
CHEMBL ID324846
CHEBI ID28837
SCHEMBL ID3933
MeSH IDM0098908

Synonyms (163)

Synonym
enantic acid
0ctanoic acid
n-octoic acid
nsc5024 ,
octic acid
wln: qv7
nsc-5024
acido octanoico
acidum octanoicum
octansaeure
c8:0
kaprylsaeure
acide octanoique
ch3-[ch2]6-cooh
acidum octanocium
CHEBI:28837 ,
octanoic acid [usan:inn]
hsdb 821
ai3-04162
ccris 4689
acido octanoico [spanish]
hexacid 898
einecs 204-677-5
acide octanoique [french]
fema no. 2799
brn 1747180
caprylic acid (natural)
nsc 5024
acidum octanocium [latin]
kyselina kaprylova [czech]
caprylsaeure
octylate
octanoic acid (usan/inn)
caprylic acid (nf)
D05220
octanoic acid (caprylic acid)
NCGC00090957-01
NCGC00090957-02
124-07-2
caprylic acid
octylic acid
octoic acid
n-octylic acid
n-octanoic acid
1-heptanecarboxylic acid
c-8 acid
C06423
n-caprylic acid
octanoic acid
octanoic acid, >=99%
octanoic acid, >=98%, fg
octanoic acid, >=98%
octanoic acid, natural, >=98%, fg
DB04519
LMFA01010008
NCIOPEN2_002902
NCIOPEN2_009358
MLS002415762
smr001252279
43FDA9D7-2300-41E7-A373-A34F25B81553
AKOS000118802
BMSE000502
octanoic acid (usan)
prifac-2901
edenor c 8-98-100
kortacid-0899
CHEMBL324846
FT-0660765
O0027
fa(8:0)
fatty acid 8:0
fa 8:0
QSPL 011
NCGC00090957-03
NCGC00090957-04
QSPL 184
NCGC00254446-01
NCGC00258831-01
tox21_300345
tox21_201279
dtxcid501645
tox21_111045
dtxsid3021645 ,
cas-124-07-2
HMS2270A23
STL282742
68937-74-6
unii-obl58jn025
ec 204-677-5
obl58jn025 ,
kyselina kaprylova
4-02-00-00982 (beilstein handbook reference)
S6296
287111-06-2
287111-23-3
287111-08-4
gtpl4585
caprylic acid [ep monograph]
caprylic acid (constituent of saw palmetto) [dsc]
caprylic acid [inci]
caprylic acid [mi]
octanoic acid [who-dd]
octanoic acid [fhfi]
caprylic acid [usp-rs]
caprylic acid [vandf]
octanoic acid [inn]
octanoic acid [ii]
octanoic acid [mart.]
caprylic acid [nf]
octanoic acid [hsdb]
octanoic acid [usan]
caprylic acid [ep impurity]
SCHEMBL3933
emery 657
lunac 8-95
prifac 2901
heptane-1-carboxylic acid
1-octanoic acid
n-heptanecarboxylic acid
octanic acid
acid c8
mfcd00004429
J-005040
caprylic acid, european pharmacopoeia (ep) reference standard
sr-01000865607
SR-01000865607-2
octanoic acid, >=96.0%
octanoic acid, analytical standard
caprylic acid, united states pharmacopeia (usp) reference standard
octanoic acid, certified reference material, tracecert(r)
bdbm50485608
octanoic acid, for synthesis, 99.5%
caprylic acid (octanoic acid), pharmaceutical secondary standard; certified reference material
kortacid 0899
lunac 8-98
CS-0016549
HY-41417
copper as octanoate
Q409564
caprylic acid (octanoic acid)
BRD-K35170555-001-07-9
STR10050
caprylic-acid
NCGC00090957-05
n-octanoicacid
is_d15-octanoic acid
EN300-21305
caprylsaure
caprylic acid (ep monograph)
octanoic acid (ii)
caprylic acid (constituent of saw palmetto)
caprylic acid (usp-rs)
usepa/opp pesticide code:128919
ch3-(ch2)6-cooh
acidum octanocium (latin)
caprylic acid (ep impurity)
octanoic acid (mart.)
naa 82
BP-27909
octanoic acid, ?99%
Z104495238
octanoic acid-7-13c
caprylic acid-8-13c

Research Excerpts

Overview

Octanoic acid is a medium-chained saturated fatty acid. It is found abundantly in the ketogenic dietary supplements containing medium chained triglycerides (MCT) along with decanoic acids. Octanoic Acid is an industrially relevant compound with applications in antimicrobials or as a precursor for biofuels.

ExcerptReferenceRelevance
"MCFA octanoic acid is a central signaling nutrient that targets POMC neurons via distinct direct and indirect signal transduction pathways to instigate changes in energy status. "( A Neural basis for Octanoic acid regulation of energy balance.
Brown, RD; De Souza, D; Dodd, GT; Haynes, VR; Michael, NJ; Spanswick, D; van den Top, M; Watt, MJ; Zhao, FY, 2020
)
1.4
"Octanoic acid is a medium-chained saturated fatty acid found abundantly in the ketogenic dietary supplements containing medium chained triglycerides (MCT) along with decanoic acid. "( Octanoic acid a major component of widely consumed medium-chain triglyceride ketogenic diet is detrimental to bone.
Jain, S; Rai, R; Singh, D; Vohora, D, 2021
)
3.51
"Octanoic acid is an industrially relevant compound with applications in antimicrobials or as a precursor for biofuels. "( High-Throughput Screening of an Octanoic Acid Producer Strain Library Enables Detection of New Targets for Increasing Titers in
Baumann, L; Boles, E; Bruder, S; Kabisch, J; Oreb, M, 2021
)
2.35
"Octanoic acid is a medium chain fatty acid, whose oxidation is not dependent on the carnitine transferase system and is not inhibited by TDGA."( Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse (db/db).
Bahl, JJ; Bressler, R; Lee, SM, 1985
)
1.23

Effects

Octanoic acid has been implicated in the pathogenesis of cytotoxic cerebral edema in Reye's syndrome.

ExcerptReferenceRelevance
"Octanoic acid has been reported as one of the nematicides, and its mode of action is not fully understood."( Transcriptomic and physiological analysis of the effect of octanoic acid on Meloidogyne incognita.
Gao, Z; Guo, C; Li, QY; Qu, JP; Ren, L; Wang, HF; Wang, JY; Zhang, Q; Zhou, B, 2023
)
1.87
"Octanoic acid has been implicated in the pathogenesis of cytotoxic cerebral edema in Reye's syndrome. "( Octanoic acid inhibits astrocyte volume control: implications for cerebral edema in Reye's syndrome.
Holtzman, D; Lawson, C; Olson, JE; Rosenberg, R; Sankar, R, 1989
)
3.16

Treatment

Treatment with octanoic acid failed to change the level of dopamine, serotonin, and 3,4-dihydroxyphenylacetic acid in the caudate and the hypothalamus. Rats treated withOctanoic Acid displayed extensive ultrastructural disruptions in the epithelial cells of the choroid plexus.

ExcerptReferenceRelevance
"Treatment with octanoic acid also failed to change the level of dopamine, serotonin, and 3,4-dihydroxyphenylacetic acid in the caudate and the hypothalamus."( Octanoic acid produces accumulation of monoamine acidic metabolites in the brain: interaction with organic anion transport at the choroid plexus.
Breese, GR; Kim, CS; Mann, JD; Roe, CR, 1992
)
2.07
"Rats treated with octanoic acid displayed extensive ultrastructural disruptions in the epithelial cells of the choroid plexus."( L-Carnitine prevents mitochondrial damage induced by octanoic acid in the rat choroid plexus.
Ambrose, WW; Kim, CS; Roe, CR, 1990
)
0.85

Toxicity

ExcerptReferenceRelevance
" The incidence of early adverse reactions (all mild) was similar for both antivenoms (15% and 24%; P>0."( Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia.
Alzate, C; Arrieta, AB; Arroyo, Y; Ayala, S; Barona, J; Conrado, LL; Córdoba, E; Díaz, A; Fabra, PE; Fernández, D; Fernández, J; Gutiérrez, JM; León, G; López, M; Meza, JJ; Mosquera, D; Núñez, V; Ospina, CE; Otero, R; Paniagua, CA; Quintana, JC; Ramírez, E; Ramírez, P; Rodríguez, V; Rojas, G; Silva, JF; Theakston, RD; Toro, MF; Warrell, DA, 2006
)
0.33
"51) in the incidence of early adverse reactions to antivenom administration (28."( Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia.
Angulo, Y; Arrieta, AB; Arroyo, Y; Barona, J; Betancur, D; Conrado, NL; Córdoba, EA; Díaz, A; Estrada, S; Fabra, P; Fernández, D; Fernández, J; Gómez, JP; Gutiérrez, JM; Herrera, M; León, G; Mosquera, DC; Ortiz, R; Otero-Patiño, R; Perea, M; Pereañez, A; Pupo, L; Quintana, JC; Ramírez, CE; Ramírez, P; Rivero, A; Segura, A; Suárez, AM; Vargas, LJ, 2012
)
0.38
" C10 is more toxic at lower concentrations than C8."( New insights into the toxicity mechanism of octanoic and decanoic acids on Saccharomyces cerevisiae.
Borrull, A; Cordero-Otero, R; López-Martínez, G; Poblet, M; Rozès, N, 2015
)
0.42
" In the present study, safe and effective ionic liquids for transdermal absorption were obtained as salts generated by a neutralization reaction between highly biocompatible aliphatic carboxylic acids (octanoic acid or isostearic acid) and aliphatic amines (diisopropanolamine or triisopropanolamine) (Medrx Co."( The molecular assembly of the ionic liquid/aliphatic carboxylic acid/aliphatic amine as effective and safety transdermal permeation enhancers.
Kubota, K; Shibata, A; Yamaguchi, T, 2016
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were determined after the third infusion of each product."( Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
Ballow, M; Berger, M; Bonilla, FA; Buckley, RH; Cunningham-Rundles, CH; Fireman, P; Kaliner, M; Lathia, C; Ochs, HD; Skoda-Smith, S; Sweetser, MT; Taki, H, 2003
)
0.32
"The pharmacokinetic profiles observed in these trials indicate that IGIV-C, 10% may replace, and be administered in a manner similar to, IGIV-SD, 10%."( Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
Ballow, M; Berger, M; Bonilla, FA; Buckley, RH; Cunningham-Rundles, CH; Fireman, P; Kaliner, M; Lathia, C; Ochs, HD; Skoda-Smith, S; Sweetser, MT; Taki, H, 2003
)
0.32
" Compared with oral administration, maximum plasma concentration (Cmax) was significantly lower, and time to reach Cmax (Tmax) delayed with all formulated tenoxicam TDS."( Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
Chun, I; Gwak, H; Kang, E; Kim, T, 2008
)
0.35
" The pharmacokinetic parameters were calculated using the MULTI computer program."( Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats.
Cho, CW; Choi, JS; Shin, SC; Yang, KH, 2009
)
0.35
"To investigate the possible use of a (13)C-uracil breath test for gastric emptying by evaluating the pharmacokinetic properties of (13)C-uracil in a breath test in rats, in comparison with (13)C-acetate and (13)C-octanoate, traditional (13)C-probes for gastric emptying."( Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats.
Hirao, Y; Inada, M; Kashimoto, M; Kunizaki, J; Sato, H; Sugiyama, E; Tobita, K; Yoshida, T, 2009
)
0.35
"This study showed that (13)C-uracil has desirable pharmacokinetic properties as an in vivo probe of gastric emptying."( Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats.
Hirao, Y; Inada, M; Kashimoto, M; Kunizaki, J; Sato, H; Sugiyama, E; Tobita, K; Yoshida, T, 2009
)
0.35
" The half-life of OA was 87."( An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
Bowen, D; Buchwald, P; Dong, C; Grimes, GJ; Hallett, M; Haubenberger, D; Ippolito, D; Kalowitz, D; Nahab, FB; Potti, G; Starling, J; Toro, C; Wittevrongel, L, 2011
)
0.37
"5 and 5 mg PTH134 (containing 200 mg 5-CNAC) demonstrated Cmax and AUC0-last values closest to those of sc teriparatide 20 μg (Forsteo®)."( The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women.
Arnold, M; Azria, M; Hämmerle, SP; Harfst, E; John, MR; Kiese, B; Launonen, A; Loeffler, R; Mindeholm, L, 2012
)
0.38
"The biodistribution data suggest that (EH)3 is able to improve the pharmacokinetic properties of peptidic radiopharmaceuticals, leading to reduced uptake in organs such as the liver, an important site of metastatic disease."( Pharmacokinetic properties of peptidic radiopharmaceuticals: reduced uptake of (EH)3-conjugates in important organs.
Bauder-Wüst, U; Eder, M; Eisenhut, M; Haberkorn, U; Löhr, T; Mier, W; Reber, M; Schäfer, M, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" After rectal administration in the absence of absorption-promoter, the bioavailability of acyclovir was 37%."( The effect of fatty acids on the rectal absorption of acyclovir in rats.
Itoh, S; Kobayashi, M; Komatsu, T; Sawanoi, M; Suzuki, S; Tanabe, K; Yamazaki, M, 1990
)
0.28
" However, GM absorption was marked when 90 mg of solid SA or CA was added (the bioavailability of GM was 58% with SA, and 59% with CA)."( Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate.
Matsumoto, M; Matsumoto, Y; Murakami, C; Murakoshi, R; Tojima, T; Watanabe, Y, 1989
)
0.28
" These actions of caprylate on membranes are considered one possible mechanism by which it promotes the absorption of water-soluble and poorly absorbed drugs."( Fluorescence study of the membrane-perturbing action of sodium caprylate as related to promotion of drug absorption.
Awazu, S; Hayashi, M; Horie, T; Kajii, H, 1988
)
0.27
" The absorption enhancing activity of w/o microemulsions incorporating these lipids was evaluated in the rat using Calcein (MW = 623) a water-soluble and poorly absorbed marker molecule."( Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation.
Constantinides, PP; Ellens, H; Owen, AB; Smith, PL; Sturgis, S; Welzel, G; Yiv, SH, 1996
)
0.29
" The development of oral heparin therapy, based on combining heparin with the carrier molecule Sodium N-(8[2-hydroxybenzoyl]amino) caprylate (SNAC) to enhance its intestinal absorption and bioavailability for the prophylaxis and treatment of DVT has been demonstrated to be effective in animal models."( Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis.
Money, SR; York, JW, 2001
)
0.31
"To study the relationship between cellular membrane fluidity and relative bioavailability (Fr) of protein and peptide drugs combined with absorption enhancers after pulmonary administration in rats."( [Study on pulmonary delivery of peptide drugs in rats: effects of absorption enhancers on cellular membrane fluidity].
Wang, ZY; Zhang, Q, 2003
)
0.32
"Tacrolimus is characterized by a highly variable oral bioavailability and narrow therapeutic window."( The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients.
Claes, K; Evenepoel, P; Kuypers, DR; Maes, B; Vanrenterghem, Y, 2004
)
0.52
" The pharmacokinetics and bioavailability of pranoprofen, an anti-inflammatory drug, were examined to determine the feasibility of an enhanced transdermal delivery system for pranoprofen from an EVA matrix containing caprylic acid as the enhancer in rats."( Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats.
Cho, CW; Choi, JS; Shin, SC; Yang, KH, 2009
)
0.35
"All the (13)C-probes employed were well absorbed from the intestine after intraduodenal administration."( Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats.
Hirao, Y; Inada, M; Kashimoto, M; Kunizaki, J; Sato, H; Sugiyama, E; Tobita, K; Yoshida, T, 2009
)
0.35
" Such binding plays a crucial role in determining the ADME (absorption, distribution, metabolism, and excretion) and bioavailability of the pollutants."( Combined fluorescence and electrochemical investigation on the binding interaction between organic acid and human serum albumin.
Chen, YM; Guo, LH, 2009
)
0.35
" By optimizing the mixed oil formulation, the absolute amount of surfactant in drug-loaded microemulsions was reduced but increased drug oral bioavailability in rats was maintained."( Optimized mixed oils remarkably reduce the amount of surfactants in microemulsions without affecting oral bioavailability of ibuprofen by simultaneously enlarging microemulsion areas and enhancing drug solubility.
Chen, Y; Hu, H; Huang, H; Liu, D; Mai, J; Song, J; Tuo, J; Wu, C; Xie, Y; You, X, 2015
)
0.42
" The performed cytotoxicity, cell apoptosis and pharmacokinetic experiments showed an enhanced bioavailability of BUF after encapsulation."( In situ phase transition of microemulsions for parenteral injection yielding lyotropic liquid crystalline carriers of the antitumor drug bufalin.
Angelova, A; Drechsler, M; Garamus, VM; Gong, Y; Li, N; Li, Y; Liu, J; Zou, A, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Sixteen participants with a diagnosis of EVT were randomized to a 3-week dosing condition of octanoic acid or placebo. Magnitude of amplitude and frequency tremor were significantly lower after 3 weeks of octonoic acid dosing as compared to the placebo condition.

ExcerptRelevanceReference
" The hourly 14CO2 production was measured for 12 h for estimating the oxidation rate of dosed triacylglycerols."( Limits of medium-chain and long-chain triacylglycerol utilization by neonatal piglets.
Chiang, SH; Clarke, SD; Cornelius, SG; Pettigrew, JE, 1990
)
0.28
" The dose-response curve for NH4Cl was affected by simultaneous subcoma doses of VP and OA but not by PB."( Valproic acid induction of coma in rats: synergism with NH4+ and pentobarbital.
Lyftogt, C; Zieve, L, 1989
)
0.28
" To circumvent the effects of LCFAO inhibition, diabetic mice were dosed with TDGA and given a diet containing 9% octanoic acid."( Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse (db/db).
Bahl, JJ; Bressler, R; Lee, SM, 1985
)
0.72
" Dose-response curves were developed which showed that one-half the animals became deeply comatose with 540 mumol of intraperitoneal phenol and 100% with 600 mumol."( Encephalopathic effect of phenol in rats.
Brunner, G; Lyftogt, C; Windus-Podehl, G; Zieve, L, 1983
)
0.27
"05) with increasing MCT dosage through 9 mL of NE and 6 mL of emulsified MCT."( Utilization of medium-chain triglycerides by neonatal pigs: effects of emulsification and dose delivered.
Lin, X; Odle, J; Wieland, TM, 1993
)
0.29
" The dose-response for palmitate was similar for the increase in TG and inhibition of glucose-induced insulin secretion."( Inhibitory effects of fatty acids on glucose-regulated B-cell function: association with increased islet triglyceride stores and altered effect of fatty acid oxidation on glucose metabolism.
Grill, VE; Ling, ZC; Zhou, YP, 1996
)
0.29
" Exogenous ghrelin increased food intake in both genotypes with a bell-shaped dose-response curve that was shifted to the left in ghrelin(-/-) mice."( Energy homeostasis and gastric emptying in ghrelin knockout mice.
Buyse, J; Coulie, B; Cryns, K; De Smet, B; Depoortere, I; Moechars, D; Moreaux, B; Peeters, TL; Swennen, Q; Tack, J, 2006
)
0.33
" Objectives were to simultaneously determine plasma LD elimination, gastric emptying, and clinical response after a single intake of the same LD dosage as LD/CD--or as (LD/CD/EN) formulation on 2 consecutive days."( Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.
Bremen, D; Erdmann, C; Goetze, O; Muhlack, S; Müller, T; Schmidt, WE; Woitalla, D,
)
0.13
" None of the dosage regimens of either antivenom used guaranteed resolution of venom-induced coagulopathy within 6 h, nor did they prevent recurrences."( Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia.
Alzate, C; Arrieta, AB; Arroyo, Y; Ayala, S; Barona, J; Conrado, LL; Córdoba, E; Díaz, A; Fabra, PE; Fernández, D; Fernández, J; Gutiérrez, JM; León, G; López, M; Meza, JJ; Mosquera, D; Núñez, V; Ospina, CE; Otero, R; Paniagua, CA; Quintana, JC; Ramírez, E; Ramírez, P; Rodríguez, V; Rojas, G; Silva, JF; Theakston, RD; Toro, MF; Warrell, DA, 2006
)
0.33
" A specific dose-response enrichment of the stomach tissue C8:0 was observed as a function of dietary C8:0, supporting the hypothesis of an early preduodenal hydrolysis of medium chain triglycerides and a direct absorption at the gastric level."( Dietary Caprylic Acid (C8:0) Does Not Increase Plasma Acylated Ghrelin but Decreases Plasma Unacylated Ghrelin in the Rat.
Beauchamp, E; Dayot, S; Duby, C; Legrand, P; Lemarié, F; Rioux, V, 2015
)
0.42
"Sixteen participants with a diagnosis of EVT were randomized to a 3-week dosing condition of octanoic acid or placebo, followed by a 2-week washout period and crossover to the other condition for an additional 3 weeks."( The Effect of Octanoic Acid on Essential Voice Tremor: A Double-Blind, Placebo-Controlled Study.
Colton, RH; Hosbach-Cannon, CJ; Kelley, RT; Lowell, SY; Mihaila, D; Monahan, M, 2019
)
1.09
"Magnitude of amplitude and frequency tremor were significantly lower after 3 weeks of octanoic acid dosing as compared to the placebo condition."( The Effect of Octanoic Acid on Essential Voice Tremor: A Double-Blind, Placebo-Controlled Study.
Colton, RH; Hosbach-Cannon, CJ; Kelley, RT; Lowell, SY; Mihaila, D; Monahan, M, 2019
)
1.1
" Further research is needed to determine whether different dosing or treatment combinations can improve functional communication in EVT."( The Effect of Octanoic Acid on Essential Voice Tremor: A Double-Blind, Placebo-Controlled Study.
Colton, RH; Hosbach-Cannon, CJ; Kelley, RT; Lowell, SY; Mihaila, D; Monahan, M, 2019
)
0.87
" This report describes a novel formulation comprising a unique amphiphilic molecule, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO), that non-covalently interacts with payloads to increase drug dispersion and diffusion when dosed intratumorally (IT) into solid tumors."( Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.
Abbate, F; Bender, LH; Walters, IB, 2020
)
0.56
" Clinical correlates of treatment response were evaluated, and cumulative effects over a 2-week period of OA drug dosing were assessed."( Clinical Features of Essential Voice Tremor and Associations with Tremor Severity and Response to Octanoic Acid Treatment.
Colton, RH; Dischinat, N; Hosbach-Cannon, CJ; Kelley, RT; Lowell, SY; Mihaila, D; Monahan, M, 2021
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
straight-chain saturated fatty acidAny saturated fatty acid lacking a side-chain.
medium-chain fatty acidAny fatty acid with a chain length of between C6 and C12.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Fatty Acid Biosynthesis233
Lipoic Acid Metabolism310
fatty acid oxidation (octanoate)614
Metabolism of proteins1058144
Peptide hormone metabolism6812
Synthesis, secretion, and deacylation of Ghrelin174
Fatty Acid Oxidation (Octanoate)214

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency44.66840.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.16230.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency29.55060.000657.913322,387.1992AID1259377
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency28.61710.000214.376460.0339AID588532
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency12.42850.001530.607315,848.9004AID1224841; AID1224842; AID1224849; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.52770.000229.305416,493.5996AID1259383; AID743069; AID743075
thyroid stimulating hormone receptorHomo sapiens (human)Potency10.48500.001628.015177.1139AID1224843; AID1224895
gemininHomo sapiens (human)Potency0.44120.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.00090.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency13.33320.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Homo sapiens (human)Ki5.41000.03003.20437.8200AID678821
Solute carrier family 22 member 8Homo sapiens (human)Ki8.60000.04004.22979.0000AID678814
G-protein coupled receptor 84Homo sapiens (human)Ki19.60000.02361.29013.3100AID1546369
Solute carrier family 22 member 11Homo sapiens (human)Ki235.50000.20002.57716.1500AID678972
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)EC50 (µMol)100.00000.08903.868710.0000AID1546364; AID1546366
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
biological_processG-protein coupled receptor 84Homo sapiens (human)
neuropeptide signaling pathwayG-protein coupled receptor 84Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
urotensin II receptor activityG-protein coupled receptor 84Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
specific granule membraneG-protein coupled receptor 84Homo sapiens (human)
tertiary granule membraneG-protein coupled receptor 84Homo sapiens (human)
receptor complexG-protein coupled receptor 84Homo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (62)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1083132Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 7 (SDW control = 12.63 +/- 3.84%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1083129Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 14 (SDW control = 35.77 +/- 4.48%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1083124Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 100 umol/L after 24 hr (Rvb = 1.47 to 2.51%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1546370Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay relative to embelin2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1417295Inhibition of electric eel AChE at 10 M using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Ellman's method2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
AID678972TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT4-expressing S2 cells2002Biochimica et biophysica acta, Jun-12, Volume: 1590, Issue:1-3
Role of human organic anion transporter 4 in the transport of ochratoxin A.
AID678821TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT1-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID681800TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Octanoate: 200 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1081320Nematicidal activity against Bursaphelenchus xylophilus assessed as mortality at 0.0625 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
AID40935Inhibition of Bacillus subtilis spore germination, activity is expressed as log of the reciprocal of Casida's I50 value.1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Ion-sensitive electrode potentiometry of organic anions: application to quantitative structure-activity relationships.
AID1081321Nematicidal activity against Bursaphelenchus xylophilus assessed as mortality at 0.125 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
AID1546369Displacement of [3H]PSB-1584 from recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 measured after 6 hrs by scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1083127Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 21 (SDW control = 44.87 +/- 3.93%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1081323Nematicidal activity against Bursaphelenchus xylophilus at 0.5 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
AID1083137Nematicidal activity against Meloidogyne incognita (root-knot nematode) root-knot nematodes assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 3 (SDW control = 0.57 +/- 0.37%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1083134Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 7 (SDW control = 12.63 +/- 3.84%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1083130Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 14 (SDW control = 35.77 +/- 4.48%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1083121Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 2000 umol/L after 12 hr (Rvb = 1.79 to 3.30%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1083128Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 21 (SDW control = 44.87 +/- 3.93%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1083131Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 14 (SDW control = 35.77 +/- 4.48%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID492140Antioxidant activity assessed as formazan formation induced absorbance changes at 25 ppm at 570 nm at 37 degC for 6 hrs by MTT assay2010Journal of natural products, Jul-23, Volume: 73, Issue:7
An efficient and economical MTT assay for determining the antioxidant activity of plant natural product extracts and pure compounds.
AID1083122Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 1000 umol/L after 24 hr Rvb = 1.47 to 2.51%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1083136Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 3 (SDW control = 0.57 +/- 0.37%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1083133Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 7 (SDW control = 12.63 +/- 3.84%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1083123Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 1000 umol/L after 12 hr (Rvb = 1.79 to 3.30%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1081322Nematicidal activity against Bursaphelenchus xylophilus assessed as mortality at 0.25 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
AID678814TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT3-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID1546364Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1083135Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 3 (SDW control = 0.57 +/- 0.37%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1546366Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1083126Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 21 (SDW control = 44.87 +/- 3.93%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1417297Inhibition of equine serum BuChE at 10 M using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Ellman's method2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
AID1083120Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 2000 umol/L after 24 hr Rvb = 1.47 to 2.51%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1546365Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1083125Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 100 umol/L after 12 hr (Rvb = 1.79 to 3.30%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,134)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990192 (16.93)18.7374
1990's214 (18.87)18.2507
2000's312 (27.51)29.6817
2010's308 (27.16)24.3611
2020's108 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.96 (24.57)
Research Supply Index7.13 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index112.93 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials53 (4.46%)5.53%
Reviews26 (2.19%)6.00%
Case Studies9 (0.76%)4.05%
Observational1 (0.08%)0.25%
Other1,100 (92.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]